Wutah pendapatan YoY sajrone 12 wulan kepungkur: MacroGenics Inc. (MGNX)

Logo grafis MacroGenics, Inc. (MGNX)

MacroGenics, Inc. (MGNX) is developing the DART platform to create bispecific antibodies against tumors. Year-over-year revenue dynamics for the last 12 months are sourced from GURU.Markets, where this chart indicates that the -11.00 metric reflects the status of the current trend. MacroGenics, Inc. (MGNX) is scaling its TRIDENT pipeline through B2B partnerships, while a strategic pivot toward new conjugates optimizes R&D expenses for global growth.

MGNX MacroGenics Corp: Wutah dodolan YoY (TTM) ing interval 11.02.2024 - 17.11.2026

Ringkesan rincian data analitis MacroGenics Inc. (MGNX)

- indikator kapitalisasi bursa perusahaan:
Ringkesan analitik perusahaan:MGNX, MacroGenics Corp
Produk merek MacroGenics Corp

MacroGenics, Inc. (MGNX) expenditures for antibody development currently exceed royalty revenues. A rolling annual revenue model neutralizes seasonality, revealing the actual dynamics of the business's fundamental state. It is critical for investors to monitor this metric for hidden write-offs affecting liquidity. This perspective allows for an assessment of the efficiency of the company's cash cushion utilization. An analysis of the sales trend compared to the same period last year over a 12-month period confirms the issuer's current stage of development.